Commerce Bank Acquires Shares of 13,920 Repligen Corporation $RGEN

Commerce Bank purchased a new position in Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 13,920 shares of the biotechnology company’s stock, valued at approximately $1,899,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Avidity Partners Management LP increased its position in shares of Repligen by 54.7% during the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock worth $9,166,000 after purchasing an additional 27,500 shares in the last quarter. Swedbank AB acquired a new position in Repligen during the fourth quarter worth about $4,146,000. B. Metzler seel. Sohn & Co. AG purchased a new stake in Repligen during the 2nd quarter valued at about $3,597,000. Global Retirement Partners LLC acquired a new stake in Repligen in the 2nd quarter valued at about $655,000. Finally, Conestoga Capital Advisors LLC raised its holdings in Repligen by 10.6% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock valued at $173,360,000 after acquiring an additional 101,062 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

NASDAQ:RGEN opened at $181.69 on Wednesday. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $188.73. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The company has a 50 day moving average price of $149.17 and a 200 day moving average price of $132.22. The stock has a market capitalization of $10.25 billion, a P/E ratio of 248.89, a PEG ratio of 3.31 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same quarter in the previous year, the company earned $0.26 earnings per share. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts forecast that Repligen Corporation will post 2.06 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on RGEN. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 13th. Jefferies Financial Group restated a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Wells Fargo & Company upped their price target on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Zacks Research upgraded Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Finally, Barclays boosted their price objective on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $166.43.

Insider Buying and Selling at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.60% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.